The V122I variant of transthyretin cardiac amyloidosis showed a trend toward shorter median time to death or heart transplant compared to wild-type (36.4 vs 66.5 months; p=0.09).
Observational
No
Do patients with V122I variant transthyretin cardiac amyloidosis have worse clinical presentations and outcomes compared to those with wild-type transthyretin cardiac amyloidosis?
Patients with the V122I variant of transthyretin cardiac amyloidosis present at a younger age with more severe cardiac dysfunction compared to those with wild-type amyloidosis, with a trend toward worse clinical outcomes.
Absolute Event Rate: 36.4% vs 66.5%
p-value: p=0.09
AIMS: In the USA, transthyretin cardiac amyloidosis usually results from 'wild-type' transthyretin (senile cardiac amyloidosis SCA) or the V122I variant. PATIENTS p = 0.0002) and 96% were black compared with 3% of SCA patients (p < 0.0001). Average ejection fraction was lower among V122I patients (mean: 25% SD: 12 vs mean: 47% SD: 15; p = 0.0001), as was mean cardiac index. Median time to death or orthotopic heart transplant was 36.4 months for V122I patients and 66.5 for SCA patients (p = 0.09). CONCLUSION: In this study of patients with transthyretin cardiac amyloidosis, V122I patients presented to a tertiary academic medical center at a younger age than SCA patients but had higher levels of cardiac dysfunction, despite genetic screening availability. There was a trend toward shorter time to orthotopic heart transplant or death among V122I patients. Whether this is a result of a different biologic progression or late diagnosis requires further study.
Givens et al. (2013) conducted an observational in Transthyretin cardiac amyloidosis. V122I variant transthyretin vs. Wild-type transthyretin (senile cardiac amyloidosis) was evaluated on Time to death or orthotopic heart transplant (p=0.09). The V122I variant of transthyretin cardiac amyloidosis showed a trend toward shorter median time to death or heart transplant compared to wild-type (36.4 vs 66.5 months; p=0.09).